X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Biodexa gain rights to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa, a proprietary oral tablet formulation of rapamycin and an mTOR inhibitor, for the treatment of Familial Adenomatous Polyposis.
Lead Product(s): Sirolimus
Therapeutic Area: Genetic Disease Product Name: eRapa
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biodexa Pharmaceuticals
Deal Size: $41.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 26, 2024
Details:
Emtora plans to use the CPRIT award to complete a multicenter, randomized, placebo-controlled Phase 3 trial of eRapa (rapamycin) in patients with FAP. Patients with FAP are predisposed to the development of hundreds or even thousands of polyps in their gastrointestinal tract.
Lead Product(s): Sirolimus
Therapeutic Area: Oncology Product Name: eRapa
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Prevention & Research Institute of Texas
Deal Size: $19.9 million Upfront Cash: Undisclosed
Deal Type: Funding August 19, 2022
Details:
In patients with low-grade PCa, treatment with low dose eRapa was found to be safe and well-tolerated.
Lead Product(s): Sirolimus
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
